ACTIONABILITY KNOWLEDGE REPOSITORY
ACTIONABILITY CURATION INTERFACE
Update History
Condition: Catecholaminergic Polymorphic Ventricular Tachycardia
Gene/Gene Panel: RYR2
Context: Pediatric
2022/02/09
Released
1.0.1
Sudden cardiac death
(GroupA)
Avoidance of intense exercise
(GroupA)
11CN
Antiarrhythmic therapy with beta-blockers and consideration for more intensive therapies as indicated
(GroupA)
12CA
Internal system migration associated with MONDO name addition.
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
RYR2
⇔
0011484 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 1, WITH OR WITHOUT ATRIAL DYSFUNCTION AND/OR DILATED CARDIOMYOPATHY; CPVT1
Strong Actionability
Strong Actionability
CASQ2
⇔
0012762 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 2; CPVT2
Strong Actionability
Strong Actionability
TRDN
⇔
0014191 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 5, WITH OR WITHOUT MUSCLE WEAKNESS; CPVT5
Strong Actionability
Strong Actionability
CALM1
⇔
0013966 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 4; CPVT4
Strong Actionability
Strong Actionability
CALM2
⇔
0017990 LONG QT SYNDROME 15; LQT15
Strong Actionability
Strong Actionability
CALM3
⇔
0032915 LONG QT SYNDROME 16; LQT16
Strong Actionability
Strong Actionability
TECRL
⇔
0013529 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 3; CPVT3
Strong Actionability
Strong Actionability
2022/02/09
Released
(Under revision)
1.0.0
Sudden cardiac death
(GroupA)
Avoidance of intense exercise
(GroupA)
11CN
Antiarrhythmic therapy with beta-blockers and consideration for more intensive therapies as indicated
(GroupA)
12CA
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
RYR2
⇔
0011484 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 1, WITH OR WITHOUT ATRIAL DYSFUNCTION AND/OR DILATED CARDIOMYOPATHY; CPVT1
Strong Actionability
Strong Actionability
CASQ2
⇔
0012762 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 2; CPVT2
Strong Actionability
Strong Actionability
TRDN
⇔
0014191 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 5, WITH OR WITHOUT MUSCLE WEAKNESS; CPVT5
Strong Actionability
Strong Actionability
CALM1
⇔
0013966 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 4; CPVT4
Strong Actionability
Strong Actionability
CALM2
⇔
0017990 LONG QT SYNDROME 15; LQT15
Strong Actionability
Strong Actionability
CALM3
⇔
0032915 LONG QT SYNDROME 16; LQT16
Strong Actionability
Strong Actionability
TECRL
⇔
0013529 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 3; CPVT3
Strong Actionability
Strong Actionability
2021/09/20
Released
1.0.0
Sudden cardiac death
(GroupA)
Avoidance of intense exercise
(GroupA)
11CN
Antiarrhythmic therapy with beta-blockers and consideration for more intensive therapies as indicated
(GroupA)
12CA
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
RYR2
⇔
0011484 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 1, WITH OR WITHOUT ATRIAL DYSFUNCTION AND/OR DILATED CARDIOMYOPATHY; CPVT1
Strong Actionability
Strong Actionability
CASQ2
⇔
0012762 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 2; CPVT2
Strong Actionability
Strong Actionability
TRDN
⇔
0014191 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 5, WITH OR WITHOUT MUSCLE WEAKNESS; CPVT5
Strong Actionability
Strong Actionability
CALM1
⇔
0013966 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 4; CPVT4
Strong Actionability
Strong Actionability
CALM2
⇔
0017990 LONG QT SYNDROME 15; LQT15
Strong Actionability
Strong Actionability
CALM3
⇔
0032915 LONG QT SYNDROME 16; LQT16
Strong Actionability
Strong Actionability
TECRL
⇔
0013529 VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 3; CPVT3
Strong Actionability
Strong Actionability
2020/02/18
In Preparation
N/A
We have begun assessment of the Pediatric context for this topic